Notícias e Atividades da PMV Pharmaceuticals
Presença
Sede: Estados Unidos
PMV Pharmaceuticals é uma empresa listada sob o símbolo PMVP (US).
Executivos
Veja o organograma con seus 22 executivos principais
Biografias mais buscadas da PMV Pharmaceuticals
- David Mack, Director, President and Chief Executive Officer
- Laurie Stelzer, Chairman of the Board (starts on Jun 4 2026)
- Arnold Levine, Director
Recentes movimentos de executivos em PMV Pharmaceuticals
- Laurie Stelzer ingressará na Companhia como Chairman of the Board em 4 de jun. de 2026 (Notícia publicada em 22 de abril de 2026).
- Richard Heyman, Chairman of the Board, deixará a Companhia em 4 de jun. de 2026 (Notícia publicada em 22 de abril de 2026).
- Laura De Leon antes Vice President and Head of Clinical Operations, foi promovido a Vice President, Clinical Development Operations (Notícia publicada em 22 de abril de 2026).
Criar um alerta
para seguir os movimentos de executivos da PMV Pharmaceuticals.
Farmacêutica
PMV Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
- Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
- Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de PMV Pharmaceuticals
- PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference | PMV Pharmaceuticals, Inc.
- PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day | PMV Pharmaceuticals, Inc.
- PMV Pharma Announces Changes to its Board of Directors | PMV Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre PMV Pharmaceuticals
- PMV Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- PMV Pharmaceuticals na LinkedIn, X (Twitter) e YouTube
